| Shen, Liangfang |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
TQB2618-AK105-II-01, NCT05563480: TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 90 | RoW | TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection, Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection, TQB2618 injection; Penpulimab injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Nasopharyngeal Carcinoma | 10/23 | 05/24 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Huang, Jianhua |
NCT04948502: SaExten Vena Cava Filter System in Prevention of Pulmonary Embolism |
|
|
| Completed | N/A | 192 | RoW | SaExten vena cava filter system, SaExten VCF system, Denali inferior vena cava filter, Denali IVCF | ShenZhen KYD Biomedical Technology Co., Ltd. | Pulmonary Embolism | 01/22 | 09/22 | | |
NCT03683459: Safety and Efficacy Study of FemFlow Drug-Eluting Peripheral Balloon Catheter |
|
|
| Recruiting | N/A | 208 | RoW | FemFlow Drug-Eluting Peripheral Balloon Catheter | Lifetech Scientific (Shenzhen) Co., Ltd. | Femoral Artery Stenosis, Femoral Artery Occlusion, Popliteal Arterial Stenosis, Popliteal Artery Occlusion | 12/22 | 12/22 | | |
| Zhao, Xielan |
NCT04845399: Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A |
|
|
| Completed | 3 | 101 | RoW | Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection | Zhengzhou Gensciences Inc, Jiangsu Gensciences lnc. | Hemophilia A | 06/21 | 06/21 | | |
NCT05487976: Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor |
|
|
| Recruiting | 3 | 50 | RoW | Recombinant human activated coagulation factor VII for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hemophilia A, Hemophilia B | 04/23 | 04/23 | | |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
NCT06312475: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors |
|
|
| Recruiting | 3 | 51 | RoW | KN057 | Suzhou Alphamab Co., Ltd. | Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | 10/25 | 12/25 | | |
NCT06569108: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors |
|
|
| Recruiting | 3 | 111 | RoW | KN057 | Suzhou Alphamab Co., Ltd. | Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor | 10/26 | 12/26 | | |
NCT05707351: A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A |
|
|
| Completed | 3 | 37 | RoW | Adynovate, Antihemophilic Factor (recombinant) PEGylated, Rurioctocog Alfa Pegol | Takeda | Hemophilia A | 09/24 | 09/24 | | |
NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation |
|
|
| Active, not recruiting | 2 | 90 | RoW | Ponatinib, Iclusig, AP24534 | Otsuka Beijing Research Institute | Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | 07/22 | 12/25 | | |
NCT05421429: KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia |
|
|
| Completed | 2 | 24 | RoW | KN057 doseⅠ, KN057 dose Ⅱ, KN057 dose Ⅲ | Suzhou Alphamab Co., Ltd. | Hemophilia | 01/24 | 01/24 | | |
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 1/2 | 123 | RoW | APG-2575, Rituximab, Ibrutinib | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 12/25 | | |
| Yang, Huaping |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT04675697: Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Platinum-etoposide+Anlotinib | Xiangya Hospital of Central South University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive-stage Small-cell Lung Cancer | 12/20 | 01/21 | | |
